1
|
Ciancia M, Rataj-Baniowska M, Zinter N, Baldassarro VA, Fraulob V, Charles AL, Alvarez R, Muramatsu SI, de Lera AR, Geny B, Dollé P, Niewiadomska-Cimicka A, Krezel W. Retinoic acid receptor beta protects striatopallidal medium spiny neurons from mitochondrial dysfunction and neurodegeneration. Prog Neurobiol 2022; 212:102246. [DOI: 10.1016/j.pneurobio.2022.102246] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2021] [Revised: 12/07/2021] [Accepted: 02/04/2022] [Indexed: 12/26/2022]
|
2
|
Hałubiec P, Łazarczyk A, Szafrański O, Bohn T, Dulińska-Litewka J. Synthetic Retinoids as Potential Therapeutics in Prostate Cancer-An Update of the Last Decade of Research: A Review. Int J Mol Sci 2021; 22:10537. [PMID: 34638876 PMCID: PMC8508817 DOI: 10.3390/ijms221910537] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2021] [Revised: 09/24/2021] [Accepted: 09/26/2021] [Indexed: 12/16/2022] Open
Abstract
Prostate cancer (PC) is the second most common tumor in males. The search for appropriate therapeutic options against advanced PC has been in process for several decades. Especially after cessation of the effectiveness of hormonal therapy (i.e., emergence of castration-resistant PC), PC management options have become scarce and the prognosis is poor. To overcome this stage of disease, an array of natural and synthetic substances underwent investigation. An interesting and promising class of compounds constitutes the derivatives of natural retinoids. Synthesized on the basis of the structure of retinoic acid, they present unique and remarkable properties that warrant their investigation as antitumor drugs. However, there is no up-to-date compilation that consecutively summarizes the current state of knowledge about synthetic retinoids with regard to PC. Therefore, in this review, we present the results of the experimental studies on synthetic retinoids conducted within the last decade. Our primary aim is to highlight the molecular targets of these compounds and to identify their potential promise in the treatment of PC.
Collapse
Affiliation(s)
- Przemysław Hałubiec
- Medical Biochemistry Medical College, Jagiellonian University, 31-034 Cracow, Poland; (P.H.); (A.Ł.); (O.S.)
| | - Agnieszka Łazarczyk
- Medical Biochemistry Medical College, Jagiellonian University, 31-034 Cracow, Poland; (P.H.); (A.Ł.); (O.S.)
| | - Oskar Szafrański
- Medical Biochemistry Medical College, Jagiellonian University, 31-034 Cracow, Poland; (P.H.); (A.Ł.); (O.S.)
| | - Torsten Bohn
- Nutrition and Health Research Group 1 A-B, Department of Population Health, Luxembourg Institute of Health, 1 A-B, rue Thomas Edison, L-23 1445 Strassen, Luxembourg;
| | - Joanna Dulińska-Litewka
- Medical Biochemistry Medical College, Jagiellonian University, 31-034 Cracow, Poland; (P.H.); (A.Ł.); (O.S.)
| |
Collapse
|
3
|
Borthwick AD, Goncalves MB, Corcoran JPT. Recent advances in the design of RAR α and RAR β agonists as orally bioavailable drugs. A review. Bioorg Med Chem 2020; 28:115664. [PMID: 33069074 PMCID: PMC7588594 DOI: 10.1016/j.bmc.2020.115664] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2020] [Revised: 07/19/2020] [Accepted: 07/22/2020] [Indexed: 11/15/2022]
Abstract
Retinoic acid receptors (RARs) α, β, and γ are members of the nuclear receptor superfamily. Compounds which bind to and activate the RARs are termed retinoids which regulate a wide variety of biological processes such as vertebrate embryonic morphogenesis and organogenesis, cell growth arrest, differentiation, and apoptosis, as well as their disorders. Although many synthetic selective RARα, RARβ, and RARγ agonists have been designed and prepared, these have generally been lipophilic acids without good drug-like properties and with low oral bioavailability. Recently this has been changing and drug design approaches to highly potent and selective RARα and RARβ agonists with low lipophilicity that are orally bioavailable and less toxic have been developed, that have a range of potential therapeutic uses. This review covers these new advances.
Collapse
Affiliation(s)
| | - Maria B Goncalves
- Neuroscience Drug Discovery Unit, Wolfson Centre for Age-Related Diseases, Guy's Campus, King's College, London SE1 1UL, UK
| | - Jonathan P T Corcoran
- Neuroscience Drug Discovery Unit, Wolfson Centre for Age-Related Diseases, Guy's Campus, King's College, London SE1 1UL, UK.
| |
Collapse
|
4
|
Goncalves MB, Clarke E, Jarvis CI, Barret Kalindjian S, Pitcher T, Grist J, Hobbs C, Carlstedt T, Jack J, Brown JT, Mills M, Mumford P, Borthwick AD, Corcoran JPT. Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury. Bioorg Med Chem Lett 2019; 29:995-1000. [PMID: 30792038 PMCID: PMC6419571 DOI: 10.1016/j.bmcl.2019.02.011] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2019] [Revised: 02/06/2019] [Accepted: 02/10/2019] [Indexed: 11/20/2022]
Abstract
Oxadiazole replacement of an amide linkage in an RARα agonist template 1, followed by lead optimisation, has produced a highly potent and selective RARβ agonist 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid (10) with good oral bioavailability in the rat and dog. This molecule increases neurite outgrowth in vitro and induces sensory axon regrowth in vivo in a rodent model of avulsion and crush injury, and thus has the potential for the treatment of nerve injury.
Collapse
Affiliation(s)
- Maria B Goncalves
- Neuroscience Drug Discovery Unit, Wolfson Centre for Age-Related Diseases, Guy's Campus, King's College, London SE1 1UL, UK
| | - Earl Clarke
- Neuroscience Drug Discovery Unit, Wolfson Centre for Age-Related Diseases, Guy's Campus, King's College, London SE1 1UL, UK
| | - Christopher I Jarvis
- Neuroscience Drug Discovery Unit, Wolfson Centre for Age-Related Diseases, Guy's Campus, King's College, London SE1 1UL, UK
| | - S Barret Kalindjian
- Neuroscience Drug Discovery Unit, Wolfson Centre for Age-Related Diseases, Guy's Campus, King's College, London SE1 1UL, UK
| | - Thomas Pitcher
- Neuroscience Drug Discovery Unit, Wolfson Centre for Age-Related Diseases, Guy's Campus, King's College, London SE1 1UL, UK
| | - John Grist
- Neuroscience Drug Discovery Unit, Wolfson Centre for Age-Related Diseases, Guy's Campus, King's College, London SE1 1UL, UK
| | - Carl Hobbs
- Neuroscience Drug Discovery Unit, Wolfson Centre for Age-Related Diseases, Guy's Campus, King's College, London SE1 1UL, UK
| | - Thomas Carlstedt
- Neuroscience Drug Discovery Unit, Wolfson Centre for Age-Related Diseases, Guy's Campus, King's College, London SE1 1UL, UK
| | - Julian Jack
- Neuroscience Drug Discovery Unit, Wolfson Centre for Age-Related Diseases, Guy's Campus, King's College, London SE1 1UL, UK
| | - Jane T Brown
- Sygnature Discovery Limited, Biocity, Pennyfoot Street, Nottingham NG1 1GF, UK
| | - Mark Mills
- Sygnature Discovery Limited, Biocity, Pennyfoot Street, Nottingham NG1 1GF, UK
| | - Peter Mumford
- Sygnature Discovery Limited, Biocity, Pennyfoot Street, Nottingham NG1 1GF, UK
| | | | - Jonathan P T Corcoran
- Neuroscience Drug Discovery Unit, Wolfson Centre for Age-Related Diseases, Guy's Campus, King's College, London SE1 1UL, UK.
| |
Collapse
|
5
|
Trasino SE, Tang XH, Shevchuk MM, Choi ME, Gudas LJ. Amelioration of Diabetic Nephropathy Using a Retinoic Acid Receptor β2 Agonist. J Pharmacol Exp Ther 2018; 367:82-94. [PMID: 30054312 DOI: 10.1124/jpet.118.249375] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Accepted: 07/20/2018] [Indexed: 12/17/2022] Open
Abstract
Vitamin A (VA) and its derivatives, known as retinoids, play critical roles in renal development through retinoic acid receptor β2 (RARβ2). Disruptions in VA signaling pathways are associated with the onset of diabetic nephropathy (DN). Despite the known role of RARβ2 in renal development, the effects of selective agonists for RARβ2 in a high-fat diet (HFD) model of DN are unknown. Here we examined whether AC261066 (AC261), a highly selective agonist for RARβ2, exhibited therapeutic effects in a HFD model of DN in C57BL/6 mice. Twelve weeks of AC261 administration to HFD-fed mice was well tolerated with no observable side effects. Compared with HFD-fed mice, HFD + AC261-treated mice had improved glycemic control and reductions in proteinuria and urine albumin-to-creatinine ratio. Several cellular hallmarks of DN were mitigated in HFD + AC261-treated mice, including reductions in tubule lipid droplets, podocyte (POD) effacement, endothelial cell collapse, mesangial expansion, and glomerular basement membrane thickening. Mesangial and tubule interstitial expression of the myofibroblast markers α-smooth muscle actin (α-SMA) and type IV collagen (Col-IV) was lower in HFD + AC261-treated mice compared with HFD alone. Ultrastructural and immunohistochemistry analyses showed that, compared with HFD-fed mice, HFD + AC261-treated mice showed preservation of POD foot process and slit-diaphragm morphology, an increase in the levels of slit-diagram protein podocin, and the transcription factor Wilms tumor-suppressor gene 1 in PODs. Given the need for novel DN therapies, our results warrant further studies of the therapeutic properties of AC261 in DN.
Collapse
Affiliation(s)
- Steven E Trasino
- Departments of Pharmacology (S.E.T., X.-H.T., L.J.G.) and Pathology (M.M.S.) and Division of Nephrology and Hypertension, Department of Medicine (M.E.C.), Weill Cornell Medical College of Cornell University, School of Urban Public Health, Nutrition Program, Hunter College, City University of New York (S.E.T.), and NewYork-Presbyterian Hospital-Weill Cornell Medical Center (M.E.C.), New York, New York
| | - Xiao-Han Tang
- Departments of Pharmacology (S.E.T., X.-H.T., L.J.G.) and Pathology (M.M.S.) and Division of Nephrology and Hypertension, Department of Medicine (M.E.C.), Weill Cornell Medical College of Cornell University, School of Urban Public Health, Nutrition Program, Hunter College, City University of New York (S.E.T.), and NewYork-Presbyterian Hospital-Weill Cornell Medical Center (M.E.C.), New York, New York
| | - Maria M Shevchuk
- Departments of Pharmacology (S.E.T., X.-H.T., L.J.G.) and Pathology (M.M.S.) and Division of Nephrology and Hypertension, Department of Medicine (M.E.C.), Weill Cornell Medical College of Cornell University, School of Urban Public Health, Nutrition Program, Hunter College, City University of New York (S.E.T.), and NewYork-Presbyterian Hospital-Weill Cornell Medical Center (M.E.C.), New York, New York
| | - Mary E Choi
- Departments of Pharmacology (S.E.T., X.-H.T., L.J.G.) and Pathology (M.M.S.) and Division of Nephrology and Hypertension, Department of Medicine (M.E.C.), Weill Cornell Medical College of Cornell University, School of Urban Public Health, Nutrition Program, Hunter College, City University of New York (S.E.T.), and NewYork-Presbyterian Hospital-Weill Cornell Medical Center (M.E.C.), New York, New York
| | - Lorraine J Gudas
- Departments of Pharmacology (S.E.T., X.-H.T., L.J.G.) and Pathology (M.M.S.) and Division of Nephrology and Hypertension, Department of Medicine (M.E.C.), Weill Cornell Medical College of Cornell University, School of Urban Public Health, Nutrition Program, Hunter College, City University of New York (S.E.T.), and NewYork-Presbyterian Hospital-Weill Cornell Medical Center (M.E.C.), New York, New York
| |
Collapse
|
6
|
Marino A, Sakamoto T, Tang XH, Gudas LJ, Levi R. A Retinoic Acid β2-Receptor Agonist Exerts Cardioprotective Effects. J Pharmacol Exp Ther 2018; 366:314-321. [PMID: 29907698 DOI: 10.1124/jpet.118.250605] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Accepted: 06/04/2018] [Indexed: 12/20/2022] Open
Abstract
We previously discovered that oral treatment with AC261066, a synthetic selective agonist for the retinoic acid β2-receptor, decreases oxidative stress in the liver, pancreas, and kidney of mice fed a high-fat diet (HFD). Since hyperlipidemic states are causally associated with myocardial ischemia and oxidative stress, we have now investigated the effects of AC261066 in an ex vivo ischemia/reperfusion (I/R) injury model in hearts of two prototypic dysmetabolic mice. We found that a 6-week oral treatment with AC261066 in both genetically hypercholesterolemic (ApoE-/-) and obese (HFD-fed) wild-type mice exerts protective effects when their hearts are subsequently subjected to I/R ex vivo in the absence of added drug. In ApoE-/- mice this cardioprotection ensued without hyperlipidemic changes. Cardioprotection consisted of attenuation of infarct size, diminution of norepinephrine (NE) spillover, and alleviation of reperfusion arrhythmias. This cardioprotection was associated with a reduction in oxidative stress and mast cell (MC) degranulation. We suggest that the reduction in myocardial injury and adrenergic activation, and the antiarrhythmic effects, result from decreased formation of oxygen radicals and toxic aldehydes known to elicit the release of MC-derived renin, promoting the activation of the local renin-angiotensin system leading to enhanced NE release and reperfusion arrhythmias. Because these beneficial effects of AC261066 occurred at the ex vivo level following oral drug treatment, our data suggest that AC261066 could be viewed as a therapeutic means to reduce I/R injury of the heart, and potentially also be considered in the treatment of other cardiovascular ailments such as chronic arrhythmias and cardiac failure.
Collapse
Affiliation(s)
- Alice Marino
- Department of Pharmacology, Weill Cornell Medicine, New York, New York
| | - Takuya Sakamoto
- Department of Pharmacology, Weill Cornell Medicine, New York, New York
| | - Xiao-Han Tang
- Department of Pharmacology, Weill Cornell Medicine, New York, New York
| | - Lorraine J Gudas
- Department of Pharmacology, Weill Cornell Medicine, New York, New York
| | - Roberto Levi
- Department of Pharmacology, Weill Cornell Medicine, New York, New York
| |
Collapse
|
7
|
Haffez H, Chisholm DR, Tatum NJ, Valentine R, Redfern C, Pohl E, Whiting A, Przyborski S. Probing biological activity through structural modelling of ligand-receptor interactions of 2,4-disubstituted thiazole retinoids. Bioorg Med Chem 2018; 26:1560-1572. [PMID: 29439915 PMCID: PMC5933457 DOI: 10.1016/j.bmc.2018.02.002] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2017] [Revised: 12/18/2017] [Accepted: 02/02/2018] [Indexed: 01/04/2023]
Abstract
Retinoids, such as all-trans-retinoic acid (ATRA), regulate cellular differentiation and signalling pathways in chordates by binding to nuclear retinoic acid receptors (RARα/β/γ). Polar interactions between receptor and ligand are important for binding and facilitating the non-polar interactions and conformational changes necessary for RAR-mediated transcriptional regulation. The constraints on activity and RAR-type specificity with respect to the structural link between the polar and non-polar functions of synthetic retinoids are poorly understood. To address this, predictions from in silico ligand-RAR docking calculations and molecular dynamics simulations for a small library of stable, synthetic retinoids (designated GZ series) containing a central thiazole linker structure and different hydrophobic region substituents, were tested using a ligand binding assay and a range of cellular biological assays. The docking analysis showed that these thiazole-containing retinoids were well suited to the binding pocket of RARα, particularly via a favorable hydrogen bonding interaction between the thiazole and Ser232 of RARα. A bulky hydrophobic region (i.e., present in compounds GZ23 and GZ25) was important for interaction with the RAR binding pockets. Ligand binding assays generally reflected the findings from in silico docking, and showed that GZ25 was a particularly strongly binding ligand for RARα/β. GZ25 also exhibited higher activity as an inducer of neuronal differentiation than ATRA and other GZ derivatives. These data demonstrate that GZ25 is a stable synthetic retinoid with improved activity which efficiently regulates neuronal differentiation and help to define the key structural requirements for retinoid activity enabling the design and development of the next generation of more active, selective synthetic retinoids as potential therapeutic regulators of neurogenesis.
Collapse
Key Words
- atra, all-trans retinoic acid
- af, activation function
- esi, electronic supplementary information
- gz, compound series code
- h12, helix 12
- lbd, ligand binding domain
- rar, retinoic acid receptor
- rare, retinoic acid response element
- rxr, retinoid x receptor
- ttn, 1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene hydrophobic region
Collapse
Affiliation(s)
- Hesham Haffez
- Department of Biochemistry and Molecular Biology, Pharmacy College, Helwan University, Cairo, Egypt; Department of Chemistry, Centre for Sustainable Chemical Processes, Durham University, South Road, Durham DH1 3LE, UK; Department of Biosciences, Durham University, South Road, Durham DH1 3LE, UK
| | - David R Chisholm
- Department of Chemistry, Centre for Sustainable Chemical Processes, Durham University, South Road, Durham DH1 3LE, UK
| | - Natalie J Tatum
- Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle upon Tyne NE2 4HH, UK
| | - Roy Valentine
- High Force Research Limited, Bowburn North Industrial Estate, Bowburn, Durham DH6 5PF, UK
| | - Christopher Redfern
- Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
| | - Ehmke Pohl
- Department of Chemistry, Centre for Sustainable Chemical Processes, Durham University, South Road, Durham DH1 3LE, UK; Department of Biosciences, Durham University, South Road, Durham DH1 3LE, UK
| | - Andrew Whiting
- Department of Chemistry, Centre for Sustainable Chemical Processes, Durham University, South Road, Durham DH1 3LE, UK.
| | - Stefan Przyborski
- Department of Biosciences, Durham University, South Road, Durham DH1 3LE, UK
| |
Collapse
|
8
|
Fouladi F, Steffen KJ, Mallik S. Enzyme-Responsive Liposomes for the Delivery of Anticancer Drugs. Bioconjug Chem 2017; 28:857-868. [PMID: 28201868 DOI: 10.1021/acs.bioconjchem.6b00736] [Citation(s) in RCA: 101] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Liposomes are nanocarriers that deliver the payloads at the target site, leading to therapeutic drug concentrations at the diseased site and reduced toxic effects in healthy tissues. Several approaches have been used to enhance the ability of the nanocarrier to target the specific tissues, including ligand-targeted liposomes and stimuli-responsive liposomes. Ligand-targeted liposomes exhibit higher uptake by the target tissue due to the targeting ligand attached to the surface, while the stimuli-responsive liposomes do not release their cargo unless they expose to an endogenous or exogenous stimulant at the target site. In this review, we mainly focus on the liposomes that are responsive to pathologically increased levels of enzymes at the target site. Enzyme-responsive liposomes release their cargo upon contact with the enzyme through several destabilization mechanisms: (1) structural perturbation in the lipid bilayer, (2) removal of a shielding polymer from the surface and increased cellular uptake, (3) cleavage of a lipopeptide or lipopolymer incorporated in the bilayer, and (4) activation of a prodrug in the liposomes.
Collapse
Affiliation(s)
- Farnaz Fouladi
- Department of Pharmaceutical Sciences, North Dakota State University , Fargo, North Dakota 58108, United States
| | - Kristine J Steffen
- Department of Pharmaceutical Sciences, North Dakota State University , Fargo, North Dakota 58108, United States
| | - Sanku Mallik
- Department of Pharmaceutical Sciences, North Dakota State University , Fargo, North Dakota 58108, United States
| |
Collapse
|
9
|
Elladiou M, Patrickios CS. A dimethacrylate cross-linker cleavable under thermolysis or alkaline hydrolysis conditions: synthesis, polymerization, and degradation. Chem Commun (Camb) 2016; 52:3135-8. [DOI: 10.1039/c5cc09445c] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
2,6-Pyridinediethanol diesters can be incorporated in polymers conveying selective alkaline hydrolytic lability and acid stability, in addition to thermolyzability.
Collapse
Affiliation(s)
- Marios Elladiou
- Department of Chemistry
- University of Cyprus
- 1678 Nicosia
- Cyprus
| | | |
Collapse
|
10
|
Sundén H, Holland MC, Poutiainen PK, Jääskeläinen T, Pulkkinen JT, Palvimo JJ, Olsson R. Synthesis and Biological Evaluation of Second-Generation Tropanol-Based Androgen Receptor Modulators. J Med Chem 2015; 58:1569-74. [DOI: 10.1021/jm501995n] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Affiliation(s)
- Henrik Sundén
- Department
of Chemistry and Molecular Biology, Medicinal Chemistry, University of Gothenburg, SE-41296 Gothenburg, Sweden
| | - Mareike C. Holland
- Department
of Chemistry and Molecular Biology, Medicinal Chemistry, University of Gothenburg, SE-41296 Gothenburg, Sweden
| | - Pekka K. Poutiainen
- School
of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
- Harvard
Medical School, Athinoula A. Martinos Center for Biomedical Imaging,
Department of Radiology, Massachusetts General Hospital, Charlestown, Massachusetts 02129, United States
| | - Tiina Jääskeläinen
- Institute
of Dentistry, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
- Institute
of Biomedicine, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Juha T. Pulkkinen
- School
of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Jorma J. Palvimo
- Institute
of Biomedicine, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
- Department
of Pathology, Kuopio University Hospital, FI-70029 Kuopio, Finland
| | - Roger Olsson
- Department
of Chemistry and Molecular Biology, Medicinal Chemistry, University of Gothenburg, SE-41296 Gothenburg, Sweden
- Chemical Biology & Therapeutics, Department of Experimental Medical Science, Lund University, Sölvegatan 19, BMC DIO, S-22184 Lund, Sweden
| |
Collapse
|
11
|
Arouri A, Hansen AH, Rasmussen TE, Mouritsen OG. Lipases, liposomes and lipid-prodrugs. Curr Opin Colloid Interface Sci 2013. [DOI: 10.1016/j.cocis.2013.06.001] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
12
|
Zhou GL, Tams DM, Marder TB, Valentine R, Whiting A, Przyborski SA. Synthesis and applications of 2,4-disubstituted thiazole derivatives as small molecule modulators of cellular development. Org Biomol Chem 2013; 11:2323-34. [PMID: 23429427 DOI: 10.1039/c3ob00005b] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Understanding how the structure of molecules relates to their function and biological activity is essential in the development of new analogues with targeted activity. This is especially relevant in mediating developmental processes in mammalian cells and the regulation of stem cell differentiation. In this study, thiazole-containing small molecules were synthesised and investigated for their ability to induce the differentiation of human pluripotent stem cells and their derivatives. Analyses of cell morphology, cell viability, expression of cell surface markers and ability to induce cell differentiation and regulate neurite formation identified the analogue with the longest and most bulky hydrophobic side chain as possessing comparable or enhanced activity to all-trans-retinoic acid (ATRA). Interestingly, a shorter, less bulky, known thiazole compound reported to be isoform selective for the retinoic acid receptor β2 (RARβ2) agonist did not mediate differentiation under the conditions tested; however, activity could be restored by adjusting the structure to a longer, more bulky molecule. These data provide further insight into the complexity of compound design in terms of developing small molecules with specific biological activities to control the development and differentiation of mammalian cells.
Collapse
Affiliation(s)
- Garr-Layy Zhou
- Department of Chemistry, Durham University, Science Laboratories, South Road, Durham, DH1 3LE, UK
| | | | | | | | | | | |
Collapse
|
13
|
Sundén H, Ma JN, Hansen LK, Gustavsson AL, Burstein ES, Olsson R. Design of a highly selective and potent class of non-planar estrogen receptor β agonists. ChemMedChem 2013; 8:1283-94. [PMID: 23784708 DOI: 10.1002/cmdc.201300175] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2013] [Indexed: 11/07/2022]
Abstract
Selective activation of the estrogen receptor β (ERβ) could be a safe approach to hormone replacement therapy for both women and men, in contrast to the estrogens currently used for women which activate both ERβ and ERα, occasionally causing severe side effects. The selective ERβ agonist AC-131 has shown efficacy in animal models of Parkinson's disease and neuropathic pain. With the use of AC-131 as template, herein we report the discovery, synthesis, and structure-activity relationship (SAR) study of a new class of dihydrobenzofurans as potent and selective ERβ agonists. The SAR was established by enantioselective synthesis, molecular modeling, and whole-cell-based functional assays. The most potent diastereomer, cis-10-SR, was shown to have an EC50 value of <1 nM, potency 100-fold higher than that of AC-131. Even more interestingly, compound trans-10-SS exhibited 1000-fold ERβ/ERα selectivity while still maintaining good potency (∼10 nM). In addition, trans-10-SS showed only partial agonist activity (30-60 % Eff.) toward ERα at 10 μM. This unprecedented selectivity could be rationalized by molecular modeling. Compound trans-10-SS appears to be the first molecule to take advantage of both conservative amino acid differences found in the α- and β-faces of the binding cavities of ERα and ERβ.
Collapse
Affiliation(s)
- Henrik Sundén
- Department of Chemistry & Molecular Biology, University of Gothenburg, Kemivägen 10, 41296 Gothenburg, Sweden
| | | | | | | | | | | |
Collapse
|
14
|
Membrane-perturbing effect of fatty acids and lysolipids. Prog Lipid Res 2013; 52:130-40. [DOI: 10.1016/j.plipres.2012.09.002] [Citation(s) in RCA: 88] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2012] [Revised: 08/20/2012] [Accepted: 09/13/2012] [Indexed: 12/13/2022]
|
15
|
Elladiou M, Patrickios CS. 2-(Pyridin-2-yl)ethanol as a protecting group for carboxylic acids: chemical and thermal cleavage, and conversion of poly[2-(pyridin-2-yl)ethyl methacrylate] to poly(methacrylic acid). Polym Chem 2012. [DOI: 10.1039/c2py20601c] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
16
|
Arouri A, Mouritsen OG. Phospholipase A(2)-susceptible liposomes of anticancer double lipid-prodrugs. Eur J Pharm Sci 2011; 45:408-20. [PMID: 21946258 DOI: 10.1016/j.ejps.2011.09.013] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2011] [Revised: 09/09/2011] [Accepted: 09/10/2011] [Indexed: 11/25/2022]
Abstract
A novel approach to anticancer drug delivery is presented based on lipid-like liposome-forming anticancer prodrugs that are susceptible to secretory phospholipase A(2) (sPLA(2)) that is overexpressed in several cancer types. The approach provides a selective unloading of anticancer drugs at the target tissues, as well as circumvents the necessity for "conventional" drug loading. In our attempts to improve the performance of the liposomes in vivo, several PEGylated and non-PEGylated liposomal formulations composed of a retinoid prodrug premixed with the sPLA(2)-hydrolyzable DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) were prepared. Besides favorably modifying the physicochemical properties of the liposomes, the incorporation of DPPC and PEG-lipids in the liposomes should substantially enhance the enzymatic activity, as concluded from literature. In addition, one can reap benefits from the presumed permeability enhancing effect of the liberated fatty acids and lysolipids. The size distribution of the prepared liposomes as well as their phase behavior, enzymatic hydrolysis, and cytotoxicity, in the presence and absence of sPLA(2), were determined. The liposomes were around 100nm in diameter and in the gel/fluid coexistence region at 37°C. The enzymatic hydrolysis of the prodrug was pronouncedly accelerated upon the premixing with DPPC, and the hydrolysis was further enhanced by PEGylation. Interestingly, the faster hydrolysis of the prodrug and the released fatty acids and lysolipids from DPPC did not improve the cytotoxicity of the mixture; the effect of combining the prodrug with DPPC was additive and not synergistic. The data presented here question the significance of the permeability enhancing effects claimed for fatty acids and lysolipids at the target cell membrane, and whether these effects can be achieved using physiologically achievable concentrations of fatty acids and lysolipids.
Collapse
Affiliation(s)
- Ahmad Arouri
- MEMPHYS(1)-Center for Biomembrane Physics, Department of Physics and Chemistry, University of Southern Denmark, Odense, Denmark.
| | | |
Collapse
|
17
|
Fluorinated molecules in the diagnosis and treatment of neurodegenerative diseases. Future Med Chem 2011; 1:821-33. [PMID: 21426082 DOI: 10.4155/fmc.09.85] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
The use of fluorinated molecules as drugs and imaging agents for CNS disorders has been studied extensively over the years. Incorporating a fluorine atom into the structure of a drug changes its physiochemical properties and can thereby lead to much more desirable pharmacokinetic and pharmacodynamic properties. This change can help to facilitate blood-brain barrier permeability, which is a critical matter for drugs intended for CNS activities. Fluorine incorporation into structures of drugs for the treatment of neurodegenerative diseases has been an attractive field for drug discovery. Such incorporation can greatly influence the physicochemical properties, metabolic stability and receptor binding affinity of the resulting molecule. Some studies have shown that when a proton was substituted with fluorine, the binding or inhibitory potency was greatly increased. The fluorine-18 isotope, (18)F, is utilized in detection and diagnosis of neurodegenerative diseases, whereas (19)F compounds are used in the treatment of these diseases and in MRI. (18)F is widely used in PET imaging because it offers the advantage of a longer half-life compared with other radionuclides. It is used for imaging various receptors and transporters that have been linked to neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple system atrophy. Fluorine plays an important role in the diagnosis and treatment of many CNS diseases, including neurodegenerative disorders. The use of fluorine in the diagnosis and treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, will be discussed in this review.
Collapse
|
18
|
Arouri A, Mouritsen OG. Anticancer double lipid prodrugs: liposomal preparation and characterization. J Liposome Res 2011; 21:296-305. [DOI: 10.3109/08982104.2011.563365] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
19
|
Alvarez S, Bourguet W, Gronemeyer H, de Lera AR. Retinoic acid receptor modulators: a perspective on recent advances and promises. Expert Opin Ther Pat 2011; 21:55-63. [PMID: 21091043 DOI: 10.1517/13543776.2011.536531] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
IMPORTANCE OF THE FIELD Retinoids are currently used in the clinic for the treatment of skin diseases and acute promielocytic leukemia and are known to contribute to early development and organogenesis in embryo and throughout life. Most of these activities are primarily due to the binding of the retinoid to the retinoic acid receptors (RARs, subtypes α, β and γ). Ligand modulates, via allosteric conformational changes, the ability of RARs to interact with different sets of co-regulators. Structure-based insights on the ligand-binding domain of the ligand-bound RARs have clearly linked retinoid function to co-activator (CoA) recruitment for agonists, CoA dissociation for antagonists and corepressor stabilization for inverse agonists. AREAS COVERED IN THIS REVIEW To help understand ligand-modulated RAR action as a consequence of its interaction with different sets of co-regulators, we present the chemical engineering of subsets of retinoid chemotypes (rexinoids, i.e., the ligands of the retinoid X receptors, α, β and γ, with impact in the treatment of cancer and metabolic diseases, are not covered) that display the whole range of ligand functions, including subtype- and isotype-selectivities. WHAT THE READER WILL GAIN An understanding of the correlation of retinoid ligand structure and function. Structural insights into ligand action and retinoid chemotypes. Potential for clinical application of retinoid receptor modulators. TAKE HOME MESSAGE Potential pharmacological/therapeutic applications of these chemical tools extend beyond cancer prevention and therapy to the treatment of autoimmune and neurodegenerative diseases.
Collapse
Affiliation(s)
- Susana Alvarez
- Departamento de Química Orgánica, Facultad de Química, Universidade de Vigo, 36310 Vigo, Spain
| | | | | | | |
Collapse
|
20
|
Kling DE, Cavicchio AJ, Sollinger CA, Schnitzer JJ, Kinane TB, Newburg DS. Nitrofen induces apoptosis independently of retinaldehyde dehydrogenase (RALDH) inhibition. ACTA ACUST UNITED AC 2010; 89:223-32. [PMID: 20549697 DOI: 10.1002/bdrb.20247] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND Nitrofen is a diphenyl ether that induces congenital diaphragmatic hernia (CDH) in rodents. Its mechanism of action has been hypothesized as inhibition of the retinaldehyde dehydrogenase (RALDH) enzymes with consequent reduced retinoic acid signaling. METHODS To determine if nitrofen inhibits RALDH enzymes, a reporter gene construct containing a retinoic acid response-element (RARE) was transfected into HEK-293 cells and treated with varying concentrations of nitrofen in the presence of retinaldehyde (retinal). Cell death was characterized by caspace-cleavage microplate assays and terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) assays. Ex vivo analyses of cell viability were characterized in fetal rat lung explants using Live/Dead staining. Cell proliferation and apoptosis were assessed using fluorescent immunohistochemistry with phosphorylated histone and activated caspase antibodies on explant tissues. Nile red staining was used to identify intracellular lipid droplets. RESULTS Nitrofen-induced dose-dependent declines in RARE-reporter gene expression. However, similar reductions were observed in control-reporter constructs suggesting that nitrofen compromised cell viability. These observed declines in cell viability resulted from increased cell death and were confirmed using two independent assays. Ex vivo analyses showed that mesenchymal cells were particularly susceptible to nitrofen-induced apoptosis while epithelial cell proliferation was dramatically reduced in fetal rat lung explants. Nitrofen treatment of these explants also showed profound lipid redistribution, primarily to phagocytes. CONCLUSIONS The observed declines in nitrofen-associated retinoic acid signaling appear to be independent of RALDH inhibition and likely result from nitrofen induced cell death/apoptosis. These results support a cellular apoptotic mechanism of CDH development, independent of RALDH inhibition.
Collapse
Affiliation(s)
- David E Kling
- Department of Biology, Boston College, Chestnut Hill, Massachusetts 02467, USA.
| | | | | | | | | | | |
Collapse
|
21
|
Discovery of a class of calcium sensing receptor positive allosteric modulators; 1-(benzothiazol-2-yl)-1-phenylethanols. Bioorg Med Chem Lett 2010; 20:5918-21. [PMID: 20727747 DOI: 10.1016/j.bmcl.2010.07.077] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2010] [Revised: 07/16/2010] [Accepted: 07/18/2010] [Indexed: 01/20/2023]
Abstract
1-(Benzothiazol-2-yl)-1-(4-chlorophenyl)ethanol (1) was identified as a positive allosteric modulator (PAM) of the CaSR in a functional cell-based assay. This compound belongs to a class of compounds that is structurally distinct from other known positive allosteric modulators, for example, the phenylalkylamines cinacalcet, a modified analog (13) potently suppressed parathyroid hormone (PTH) release in rats, consistent with its profile as a PAM of CaSRs.
Collapse
|
22
|
Pedersen PJ, Adolph SK, Subramanian AK, Arouri A, Andresen TL, Mouritsen OG, Madsen R, Madsen MW, Peters GH, Clausen MH. Liposomal Formulation of Retinoids Designed for Enzyme Triggered Release. J Med Chem 2010; 53:3782-92. [DOI: 10.1021/jm100190c] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Affiliation(s)
- Palle J. Pedersen
- Department of Chemistry, Technical University of Denmark, Kemitorvet, Building 201 and 207, DK-2800 Kgs. Lyngby, Denmark
| | - Sidsel K. Adolph
- LiPlasome Pharma A/S, Technical University of Denmark, Diplomvej 378, DK-2800 Kgs. Lyngby, Denmark
| | - Arun K. Subramanian
- Department of Chemistry, Technical University of Denmark, Kemitorvet, Building 201 and 207, DK-2800 Kgs. Lyngby, Denmark
| | - Ahmad Arouri
- Department of Physics and Chemistry, MEMPHYS−Center for Biomembrane Physics, University of Southern Denmark, Campusvej 55, DK-5230 Odense M, Denmark
| | - Thomas L. Andresen
- Department of Micro- and Nanotechnology, Technical University of Denmark, DK-4000 Roskilde, Denmark
| | - Ole G. Mouritsen
- Department of Physics and Chemistry, MEMPHYS−Center for Biomembrane Physics, University of Southern Denmark, Campusvej 55, DK-5230 Odense M, Denmark
| | - Robert Madsen
- Department of Chemistry, Technical University of Denmark, Kemitorvet, Building 201 and 207, DK-2800 Kgs. Lyngby, Denmark
| | - Mogens W. Madsen
- LiPlasome Pharma A/S, Technical University of Denmark, Diplomvej 378, DK-2800 Kgs. Lyngby, Denmark
| | - Günther H. Peters
- Department of Chemistry, Technical University of Denmark, Kemitorvet, Building 201 and 207, DK-2800 Kgs. Lyngby, Denmark
| | - Mads H. Clausen
- Department of Chemistry, Technical University of Denmark, Kemitorvet, Building 201 and 207, DK-2800 Kgs. Lyngby, Denmark
| |
Collapse
|
23
|
Alvarez S, Khanwalkar H, Alvarez R, Erb C, Martínez C, Rodríguez-Barrios F, Germain P, Gronemeyer H, de Lera AR. C3 halogen and c8'' substituents on stilbene arotinoids modulate retinoic Acid receptor subtype function. ChemMedChem 2009; 4:1630-40. [PMID: 19670208 DOI: 10.1002/cmdc.200900214] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The synthesis and biological evaluation of the entire series of C3-halogenated derivatives and bulkier substituents at the C8'' position of the parent stilbene-based RARbeta-selective agonist BMS641 4 c was undertaken. The synthesis uses an E-selective Horner-Wadsworth-Emmons (HWE) condensation of C8-substituted C5-dimethyl dihydronaphthaldehyde and the benzylic phosphonates derived from the C3-halogenated benzoates to construct the stilbene skeleton. Transactivation studies revealed the synergistic effect of small halogen atoms at C3 (F, Cl) and the moderately bulky phenyl group at C8'' (in 4 b and 4 c) to achieve RARbeta selectivity. Our results, supported by computational studies, provide a structural rationale for the mixed agonist-antagonist activities of these arotinoids, which are potent agonists of the RARbeta subtype and antagonists of the RARalpha paralogue. Moreover, transitions from partial agonists to inverse agonists and antagonists can be accomplished with the incorporation of the same halogen atoms into the structures of known modulators BMS701 (5 a) and BMS493 (6 a), which have bulkier substituents than phenyl (p-tolyl and phenylethynyl, respectively) at C8''. Conversely, incorporation of halogen atoms in 6 a converted the ligand from an RARbeta inverse agonist (6 b) to an antagonist (6 c) or an agonist (6 d). Amazingly, 6 a-c commonly acted as inverse agonists for RARalpha, while 6 d and 6 e acted as regular RARalpha antagonists, not affecting co-repressor interaction. In the case of the mixed agonist/antagonist 5 a, C3-halogenation yields inverse RARalpha and RARbeta agonists (5 b-d) with the exception of iodinated 5 e, which is a regular antagonist for both these receptors. Because RARbeta gene expression is frequently deleted or epigenetically silenced in several tumor cells, the novel repertoire of receptor and function-selective RAR agonists, mixed agonist/antagonists, regular antagonists, and inverse agonists will be useful in the elucidation of the mechanism of tumor suppression by retinoids.
Collapse
Affiliation(s)
- Susana Alvarez
- Departamento de Química Orgánica, Facultade de Química, Universidade de Vigo, 36310 Vigo (Spain)
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Schlienger N, Lund BW, Pawlas J, Badalassi F, Bertozzi F, Lewinsky R, Fejzic A, Thygesen MB, Tabatabaei A, Bradley SR, Gardell LR, Piu F, Olsson R. Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators. J Med Chem 2009; 52:7186-91. [PMID: 19856921 DOI: 10.1021/jm901149c] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Herein we describe the discovery of ACP-105 (1), a novel and potent nonsteroidal selective androgen receptor modulator (SARM) with partial agonist activity relative to the natural androgen testosterone. Compound 1 was developed from a series of compounds found in a HTS screen using the receptor selection and amplification technology (R-SAT). In vivo, 1 improved anabolic parameters in a 2-week chronic study in castrated male rats. In addition to compound 1, a number of potent antiandrogens were discovered from the same series of compounds whereof one compound, 13, had antagonist activity at the AR T877A mutant involved in prostate cancer.
Collapse
|
25
|
Gaubert G, Bertozzi F, Kelly NM, Pawlas J, Scully AL, Nash NR, Gardell LR, Lameh J, Olsson R. Discovery of Selective Nonpeptidergic Neuropeptide FF2 Receptor Agonists. J Med Chem 2009; 52:6511-4. [DOI: 10.1021/jm9011998] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Gilles Gaubert
- ACADIA Pharmaceuticals AB, Medeon Science Park, S-205 12 Malmö, Sweden
| | - Fabio Bertozzi
- ACADIA Pharmaceuticals AB, Medeon Science Park, S-205 12 Malmö, Sweden
| | - Nicholas M. Kelly
- ACADIA Pharmaceuticals AB, Medeon Science Park, S-205 12 Malmö, Sweden
| | - Jan Pawlas
- ACADIA Pharmaceuticals AB, Medeon Science Park, S-205 12 Malmö, Sweden
| | - Audra L. Scully
- ACADIA Pharmaceuticals Inc., 3911 Sorrento Valley Boulevard, San Diego, California 92121
| | - Norman R. Nash
- ACADIA Pharmaceuticals Inc., 3911 Sorrento Valley Boulevard, San Diego, California 92121
| | - Luis R. Gardell
- ACADIA Pharmaceuticals Inc., 3911 Sorrento Valley Boulevard, San Diego, California 92121
| | - Jelveh Lameh
- ACADIA Pharmaceuticals Inc., 3911 Sorrento Valley Boulevard, San Diego, California 92121
| | - Roger Olsson
- ACADIA Pharmaceuticals AB, Medeon Science Park, S-205 12 Malmö, Sweden
| |
Collapse
|